
前纵隔淋巴瘤与胸腺癌能谱CT的表现差异
马拓,曹立秀,李会菊,任红亮,陈大鹏,高媛,李志东,赵新斌,董思圻
中国医学科学院学报 ›› 2020, Vol. 42 ›› Issue (4) : 431-435.
前纵隔淋巴瘤与胸腺癌能谱CT的表现差异
Different Energy Spectrum CT Findings between Anterior Mediastinal Lymphoma and Thymic Carcinoma
目的 探讨前纵隔淋巴瘤与胸腺癌能谱CT的表现差异。方法 选取唐山市人民医院穿刺活检病理证实的前纵隔淋巴瘤22例和胸腺癌28例,经能谱CT进行平扫和增强检查,应用能谱分析软件测量不同单能量下的CT值及病变部位的碘含量、水含量变化,比较前纵隔淋巴瘤和胸腺癌的差异。结果 胸腺癌动脉期和静脉期40~80 keV单能量CT值高于前纵隔淋巴瘤,差异有统计学意义(P=0.001,P=0.037,P=0.042,P=0.034,P=0.002;P=0.016,P=0.013,P=0.018,P=0.024,P=0.012);胸腺癌在90~110 keV单能量CT值与前纵隔淋巴瘤比较差异均无统计学意义(P均>0.05)。胸腺癌动脉期和静脉期水浓度低于前纵隔淋巴瘤,差异有统计学意义(P=0.030,P=0.037);碘浓度高于前纵隔淋巴瘤,差异有统计学意义(P=0.026,P=0.000)。结论 前纵隔淋巴瘤与胸腺癌在能谱CT检查40~80 keV单能量CT值及动脉期和静脉期水浓度、碘浓度上的差异显著,并可以此区分两者。
Objective To investigate the differences in energy spectrum CT findings between anterior mediastinal lymphoma and thymic carcinoma. Methods Twenty-two cases of anterior mediastinal lymphoma and 28 cases of thymic carcinoma confirmed by biopsy in Tangshan People’s Hospital were selected.The CT values and changes of iodine content and water content in lesion sites were measured by energy spectrum analysis software.The differences between anterior mediastinal lymphoma and thymic carcinoma were compared. Results The single-energy CT value of 40-80 keV in thymus carcinoma was higher than that in anterior mediastinal lymphoma(P=0.001,P=0.037,P=0.042,P=0.034,P=0.002;P=0.016,P=0.013,P=0.018,P=0.024,P=0.012).The difference in the single-energy CT value of 90-110 keV between anterior mediastinal lymphoma and thymic carcinoma showed no statistical significance(all P>0.05).The concentrations of water in the arterial and venous stages of thymic carcinoma were significantly lower than those in the anterior mediastinal lymphoma(P=0.030,P=0.037),whereas the iodine concentrations were significantly higher(P=0.026,P=0.000). Conclusion Anterior mediastinal lymphoma and thymic carcinoma have remarkably different 40-80 keV single energy CT value and iodine concentration in arterial and venous phases,which may be helpful for the differential diagnosis of these two malignancies.
前纵隔 / 淋巴瘤 / 胸腺癌 / 体层摄影术 {{custom_keyword}} /
anterior mediastinal / lymphoma / thymic carcinoma / tomography {{custom_keyword}} /
表1 动脉期增强扫描前纵隔淋巴瘤和胸腺癌单能量CT值比较( |
分组Group | n | 动脉期CT值 Arterial phase CT value | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
40 keV | 50 keV | 60 keV | 70 keV | 80 keV | 90 keV | 100 keV | 110 keV | |||
胸腺癌组 Thymic cancer group | 22 | 86.34±7.51 | 74.42±6.83 | 66.45±5.86 | 55.37±4.15 | 46.25±4.06 | 42.71±3.83 | 35.56±2.82 | 28.46±1.76 | |
淋巴瘤组 Lymphoma group | 28 | 75.82±6.76 | 68.26±5.08 | 54.73±4.26 | 43.23±3.42 | 37.71±3.28 | 31.35±3.05 | 28.36±2.62 | 21.34±2.38 | |
t | 3.572 | 1.853 | 1.482 | 1.963 | 2.082 | 0.052 | 0.073 | 0.612 | ||
P | 0.001 | 0.037 | 0.042 | 0.034 | 0.002 | 0.096 | 0.061 | 0.068 |
表2 静脉期增强扫描前纵隔淋巴瘤和胸腺癌单能量CT值比较( |
分组Group | n | 静脉期CT值 Venous phase CT value | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
40 keV | 50 keV | 60 keV | 70 keV | 80 keV | 90 keV | 100 keV | 110 keV | |||
胸腺癌组 Thymic cancer group | 22 | 132.53±23.48 | 103.48±18.64 | 83.42±8.62 | 75.58±6.75 | 68.49±6.27 | 56.86±5.45 | 48.32±4.18 | 36.73±3.43 | |
淋巴瘤组 Lymphoma group | 28 | 112.34±18.72 | 87.64± 9.56 | 69.45±7.37 | 58.41±6.62 | 51.46±5.24 | 47.26±4.43 | 41.64±3.68 | 29.25±2.49 | |
t | 2.372 | 2.385 | 2.156 | 1.766 | 2.631 | 0.073 | 0.084 | 0.093 | ||
P | 0.016 | 0.013 | 0.018 | 0.024 | 0.012 | 0.082 | 0.075 | 0.057 |
图1 前纵隔淋巴瘤感兴趣区(圆圈L1)面积60.81 mm2A.对应病灶动脉期70 keV纵隔窗图像;B.对应病灶静脉期70 keV纵隔窗图像;C.对应病灶动脉期水基图;D.对应病灶静脉期水基图;E.对应病灶动脉期碘基图;F.对应病灶静脉期碘基图Fig 1 The area of interest of anterior mediastinal lymphoma(circle L1)is 60.81 mm2 A.the image of 70 keV corresponds to the arterial phase of the lesion;B.the image of 70 keV corresponds to the venous phase of the lesion;C.the image of water base of the arterial phase of the lesion;D.corresponds to the water base map of the focus vein phase;E.corresponds to the iodine base map of the focus artery phase;F.corresponds to the iodine base map of the focus vein phase |
图2 胸腺癌感兴趣区(圆圈L2)面积56.33 mm2A.对应病灶动脉期70 keV纵隔窗图像;B.对应病灶静脉期70 keV纵隔窗图像;C.对应病灶动脉期水基图;D.对应病灶静脉期水基图;E.对应病灶动脉期碘基图;F.对应病灶静脉期碘基图Fig 2 The area of interest of thymic carcinoma(circle L2)is 56.33 mm2 A.the image of 70 keV corresponds to the arterial phase of the lesion;B.the image of 70 keV corresponds to the venous phase of the lesion;C.the image of water base of the arterial phase of the lesion;D.corresponds to the water base map of the focus vein phase;E.corresponds to the iodine base map of the focus artery phase;F.corresponds to the iodine base map of the focus vein phase |
表3 前纵隔淋巴瘤组和胸腺癌组水浓度和碘浓度的比较( |
分组Group | n | 水浓度Water concentration(mg/cm3) | 碘浓度Iodine concentration(μg/cm3) | ||
---|---|---|---|---|---|
动脉期Arterial phase | 静脉期Venous phase | 动脉期Arterial phase | 静脉期Venous phase | ||
胸腺癌组Thymic cancer group | 22 | 1031.59±10.21 | 1026.01± 7.17 | 9.63±2.19 | 12.04±1.26 |
淋巴瘤组Lymphoma group | 28 | 1046.37± 7.27 | 1040.39±10.65 | 6.69±1.01 | 7.33±0.87 |
t | -2.636 | -2.506 | 2.722 | 6.868 | |
P | 0.030 | 0.037 | 0.026 | 0.000 |
[1] |
PURPOSE: To determine the frequency and natural course of mediastinal masses in asymptomatic people at high risk for lung cancer who were undergoing computed tomographic (CT) screening. MATERIALS AND METHODS: Informed consent and institutional review board approval for this HIPAA-compliant study were obtained at each participating institution. All documented mediastinal masses among the 9263 baseline and 11 126 annual repeat screenings performed in the Early Lung Cancer Action Project (ELCAP) and its successor project, the New York ELCAP, were identified. Two radiologists confirmed all cases, identified the location and measured the diameter (average of length and width) of each mass, and reviewed all subsequent CT and clinical and surgical results. The prevalence and incidence of mediastinal masses were then determined. RESULTS: Of the 9263 individuals, 71 had a mediastinal mass seen at baseline screening (prevalence of 0.77%). Of the 71 masses, 41 were thymic, 16 were thyroidal, two were esophageal cancers, six were tracheal-esophageal diverticula, and six were other masses. Among the 11 126 annual repeat screenings, only one new mediastinal mass was identified (incidence of 0.01%). This suggests a long average duration for mediastinal masses in asymptomatic people. Among the 41 thymic masses, five were larger than 3.0 cm in diameter, and all five were resected; of these five, one was a thymic carcinoma and four were noninvasive thymomas. Of the remaining 36 thymic masses, 25 were evaluated at follow-up CT 1 year later: Five had increased in diameter, two had decreased, and 18 remained unchanged. All 16 thyroid masses were due to goiter; none of these were changed at follow-up CT 1 year later. CONCLUSION: Mediastinal masses found in the context of CT screening for lung cancer in asymptomatic people should be approached in a
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[2] |
李进叶, 宋歌声, 宋吉清, 等. 能谱CT与常规超声对甲状腺结节良恶性诊断价值的对照分析[J]. 山东大学学报:医学版, 2016,54(3):81-86.DOI: 10.6040/j.issn.1671-7554.0.2015.263.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[3] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[4] |
OBJECTIVE: To evaluate the ability of contrast-enhanced transrectal ultrasonography (CETRUS) to detect and localize prostate index tumor. METHODS: Eighty-three patients with biopsy-proven prostate cancer (PCa), who were scheduled to undergo radical prostatectomy, were enrolled in this prospective study. Each patient underwent baseline grayscale and CETRUS imaging of the prostate according to a standardized protocol before the operation. Ultrasonography findings (CETRUS and grayscale imaging) were correlated with step-section histopathology. RESULTS: Overall, 53 and 68 tumor foci were detected by grayscale imaging and CETRUS, respectively. The combination of grayscale imaging and CETRUS allowed identification of 89 of the 232 cancer foci (38.4%). The sensitivity of combined imaging was significantly superior to that of grayscale imaging (P<.01) and CETRUS (P<.05). Additionally, the prostate index tumor detection rate by the use of grayscale imaging, CETRUS, and their combination was 42 of 83 (50.6%), 53 of 83 (63.9%), and 67 of 83 (80.7%), respectively. The combined approach performed significantly better than grayscale and CETRUS imaging (P<.001 and P<.05, respectively). The index tumor detection rate of CETRUS was higher than that of grayscale imaging, but no significant difference was found (P>.05). CONCLUSION: Our study has demonstrated significantly improved detection of both PCa and index tumor with a combined approach of CETRUS and grayscale imaging compared with baseline grayscale technique only, and this technique may be applicable to focal therapy of PCa.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[5] |
张文浩, 叶丽芳, 雷永霞, 等. 纵隔淋巴瘤出现坏死的特点及相关因素分析[J]. 实用放射学杂志, 2014,30(8):1310-1312,1399.DOI: 10.3969/j.issn.1002-1671.2014.08.016.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[6] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[7] |
彭杰, 王启伟, 李鹏, 等. 能谱CT去除冠状动脉钙化性斑块硬化伪影对心血管狭窄程度的诊断价值[J]. 生物医学工程与临床, 2018,14(2):45-48.DOI: 10.13339/j.cnki.sglc.20180313.011.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[8] |
罗昆, 董仟, 杨明, 等. 双低对比剂联合能谱 CT 成像技术在门静脉成像中的应用研究[J]. 临床放射学杂志, 2016,35(11):1759-1763.DOI: 10.13437/j.cnki.jcr.2016.11.03.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[9] |
张秋杭, 高艳, 李坤成, 等. 能谱CT GSI与MARS在减除脊柱金属植入物椎管内伪影效果的研究比较[J]. 临床放射学杂志, 2012,31(9):1338-1342.DOI: 10.13437/j.cnki.jcr.2012.09.011.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[10] |
The energy spectrum of X-ray photons after passage through an absorber contains information about its elemental composition. Thus, tissue characterisation becomes feasible provided that absorption characteristics can be measured or differentiated. Dual-energy CT uses two X-ray spectra enabling material differentiation by analysing material-dependent photo-electric and Compton effects. Elemental concentrations can thereby be determined using three-material decomposition algorithms. In comparison to dual-energy CT used in clinical practice, recently developed energy-sensitive photon-counting detectors sample the material-specific attenuation curves at multiple energy levels and within narrow energy bands; the latter allows the detection of element-specific, k-edge discontinuities of the photo-electric cross section. Multi-energy CT imaging therefore is able to concurrently identify multiple materials with increased accuracy. These specific data on material distribution provide information beyond morphological CT, and approach functional imaging. This article reviews the principles of dual- and multi-energy CT imaging, hardware approaches and clinical applications.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[11] |
UNLABELLED: Dual-energy computed tomography (DECT) can amply contribute to support oncological imaging: the DECT technique offers promising clinical applications in oncological imaging for tumour detection and characterisation while concurrently reducing the radiation dose. Fast image acquisition at two different X-ray energies enables the determination of tissue- or material-specific features, the calculation of virtual unenhanced images and the quantification of contrast medium uptake; thus, tissue can be characterised and subsequently monitored for any changes during treatment. DECT is already widely used, but its potential in the context of oncological imaging has not been fully exploited yet. The technology is the subject of ongoing innovation and increasingly with respect to its clinical potential, particularly in oncology. This review highlights recent state-of-the-art DECT techniques with a strong emphasis on ongoing DECT developments relevant to oncologic imaging, and then focuses on clinical DECT applications, especially its prospective uses in areas of oncological imaging. KEY POINTS: * Dual-energy CT (DECT) offers fast, robust, quantitative and functional whole-body imaging. * DECT provides improved tumour detection and more detailed tissue differentiation and characterisation. * DECT affords therapy monitoring with complementary information and reduced radiation dose. * The use of DECT in oncology is of increasing clinical importance. * The potential of DECT in oncology has not been fully exploited yet.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[12] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[13] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[14] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 |
|
〉 |